First, what "normal" memory aging actually looks like
Before the interesting part, a number that deserves more attention than it gets. On a standard word-list test, the average person aged 56 to 66 recalls about 9 of 15 words after a delay. At age 80, the average is about 5 of 15.[1]
Sit with that for a second. Losing something close to half your delayed recall is not a disease state — it is the average. As the Northwestern researchers put it with admirable bluntness: in late life, "average" does not mean "intact." We have quietly baked substantial cognitive decline into our definition of normal aging, which means measuring yourself against your age group is a fairly forgiving benchmark.
Which is exactly why the existence of people who don't do this is such a big deal.
What actually counts as a SuperAger
The term was coined at Northwestern University's Alzheimer's Disease Research Center, and it has a real definition rather than a marketing one: a person aged 80 or older with delayed word recall at least equal to that of individuals 20 to 30 years younger.[1]
Note what that excludes. Your grandfather who is remarkably switched on for 84 is not automatically a SuperAger. The bar is not "good for their age" — it is "matches people in their fifties." That precision is the whole reason the research has been productive: define a phenotype sharply enough and you can go looking for what makes it tick.
The Northwestern programme published a summary of its first 25 years in 2025, and the headline conclusion is that SuperAgers are not merely a statistical curiosity at the top of the bell curve. They are a distinct neurobiological phenotype — their brains are physically different from those of their cognitively average peers.
The brain differences are genuinely strange
The list from that 25-year summary is worth reading slowly:[1]
- No age-related shrinkage. SuperAgers have cortical volumes no different from neurotypical adults 20 to 30 years younger — while their own age peers show the expected atrophy.
- A thicker cingulate region. Not just thicker than their peers — thicker than younger neurotypical adults. That is not "aging slowly." That is something else.
- Fewer Alzheimer's-type changes in brain tissue, plus larger entorhinal neurons — the entorhinal cortex being one of the first regions Alzheimer's disease typically attacks.
- Fewer inflammatory microglia in white matter and better-preserved cholinergic innervation, the signalling system most heavily implicated in memory.
- More von Economo neurons, a rare, large, evolutionarily recent cell type found in humans, great apes, elephants and whales, and linked to social and self-awareness processing.
A separate 2026 imaging study added another piece. Comparing 14 SuperAgers with 17 cognitively average adults over 80, researchers mapped white matter hyperintensities — the bright patches on MRI that mark small-vessel damage and accumulate with age. Overall burden was lower in SuperAgers (median 3.52 mL versus 8.52 mL), though that difference did not reach statistical significance. What was significant was regional: SuperAgers had notably less damage in specific frontal locations, particularly the juxtacortical and mid-frontal layers.[2] With 31 people total, this is a hint rather than a conclusion — but it is a specific hint about where to look.
The July 2026 study that killed the easy explanation
Here is where it gets good, because the obvious hypothesis has now been tested and it lost.
If some people sail into their nineties with intact memories, surely they simply drew better cards — low genetic risk for Alzheimer's disease. It is the tidiest possible explanation, and it has the additional appeal of letting the rest of us off the hook.
On 23 July 2026, a multi-site team published in Alzheimer's Research & Therapy a direct test of exactly that.[3] Using the SuperAging Research Initiative cohort, they compared 142 SuperAgers against 89 cognitively average controls. They examined APOE — the single strongest common genetic risk factor for Alzheimer's — and calculated three separate polygenic risk scores, each aggregating thousands of variants from large contemporary genome-wide association studies. They adjusted for age, sex and education, and confirmed the groups were comparable in genetic ancestry.
The result: nothing. APOE allele and genotype distributions did not differ between the groups. None of the three polygenic risk scores predicted SuperAger status. The findings held when accounting for non-European or African ancestry and principal components.
So SuperAging is not simply the mirror image of Alzheimer's risk. Being genetically lucky about dementia and being exceptional at 85 turn out to be different things. The authors' conclusion points onward: toward rare genetic variants that common-variant scores cannot capture, and toward what they call experiential factors — the accumulated effect of how a life was actually lived.
The part that should keep you honest
This is a site about pressure-testing claims, so let us apply the same treatment here rather than only to things we dislike.
- The samples are small. 231 people in the genetics study; 31 in the imaging study. These are hard-to-recruit cohorts by definition — you cannot manufacture 80-year-olds with 50-year-old memories — but small samples produce unstable findings, and some of these will not replicate.
- Cause and effect are unresolved. Nobody knows whether a thicker cingulate produces SuperAging or is a consequence of decades of something else. The brains were measured late; the lives were lived first. Every one of these features is compatible with either direction.
- Selection effects are everywhere. People who volunteer for a decades-long brain study, attend appointments and complete neuropsychological batteries are unusual in ways that have nothing to do with their cingulate cortex.
- A null result is not a mechanism. "It isn't APOE" is genuine progress, but it tells you where the answer isn't. The actual explanation remains unidentified.
- There is no protocol. None of this research has produced an intervention. If you see a "SuperAger method" for sale this month — and you will, because the term is far too good not to be strip-mined — that is a clean hype-detox case. The science describes these people. It cannot yet make more of them.
The clean verdict
What we find genuinely valuable here has little to do with the headline. It is the reframing.
The default model of brain aging is a slope: everyone descends, some more gracefully than others, and the best you can hope for is a gentler gradient. SuperAgers break that model. A cingulate region thicker than that of younger adults is not a gentler slope — it is evidence that substantial cognitive decline is not an inevitable feature of being 85. Some people simply do not do it, and their brains show why in physical detail.
The honest follow-up is that we cannot yet tell you how to join them. What we can say is that the July 2026 result quietly makes the picture less fatalistic, not more. If SuperAging were purely a matter of APOE and polygenic scores, it would be a lottery decided before birth and there would be nothing to do about it. That study says it isn't. Whatever is going on involves rare biology we have not found yet and, in the authors' own framing, experiential factors — the things that happen across a life.
Which is not permission to buy anything. It is a reason to keep pulling the levers that already have evidence behind them for cognitive aging: physical activity, sleep, blood pressure, hearing correction, staying socially and mentally engaged. None of those will be marketed to you as a SuperAger protocol, because nobody can put a barcode on them — which, as usual on this site, is a point in their favour rather than against. We'll keep tracking what actually holds up, and if the field ever converts this phenotype into something you can do rather than something you can be, that will be a genuinely large day. It hasn't happened yet.
Common questions
A term coined at Northwestern University's Alzheimer's Disease Research Center with a precise definition: a person aged 80 or older whose delayed word recall is at least as good as that of people 20 to 30 years younger.[1] It is not a general label for anyone sharp for their age. For scale, average delayed recall on a 15-word list is roughly 5/15 at age 80 versus about 9/15 at ages 56–66 — so SuperAgers hit the younger benchmark, not merely a good score for their own age group.
That was the obvious hypothesis, and a July 2026 study tested it directly and found no support. Researchers compared 142 SuperAgers with 89 cognitively average peers, examining APOE — the strongest common genetic risk factor for Alzheimer's — plus three polygenic risk scores aggregating thousands of variants. Neither APOE nor any of the scores predicted SuperAger status.[3] Low inherited Alzheimer's risk does not make you a SuperAger, which pushes the explanation toward rare variants and lifetime experiential factors not yet identified.
There is no evidence-based protocol, and anyone selling one is ahead of the science. The research is descriptive — it characterises people who already have the trait and cannot yet say whether their distinctive brain features caused their memory or resulted from decades of something else. What remains well supported is unglamorous: physical activity, sleep, blood pressure control, hearing correction, education and social connection are still the best-evidenced levers for cognitive aging available today.
References
- Weintraub S, Gefen T, Geula C, Mesulam MM. The first 25 years of the Northwestern University SuperAging Program. Alzheimer's & Dementia. 2025;21(8):e70312. PubMed: 40772536. doi:10.1002/alz.70312
- de Godoy LL, Sudre CH, Studart-Neto A, et al. Reduced Frontal White Matter Hyperintensities in Superagers: Evidence of Resistance to Age-Related Structural Brain Changes. AJNR Am J Neuroradiol. 2026;47(4):989-997. PubMed: 41927336. doi:10.3174/ajnr.A9084
- Piras IS, Capuano AW, Maher AC, et al. SuperAging is not the inverse of common-variant Alzheimer's risk: evidence across genetic ancestries. Alzheimer's Research & Therapy. 2026;18(1). PubMed: 42493810. doi:10.1186/s13195-026-02124-2
Study data sourced via PubMed.
